SCHEMBL303313

SCHEMBL303313

O=C(c1cccc(N(Cc2ccccc2)S(=O)(=O)c2ccccc2)c1)N1CCC(c2ccccc2)CC1

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.57
KMT2A Q03164 3/20 0.56
HPGD P15428 1/20 0.56
ALDH1A1 P00352 2/20 0.54
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA7 P43166 1/20 0.50
CA9 Q16790 1/20 0.50
CA14 Q9ULX7 1/20 0.50
PKM P14618 1/20 0.49
MEN1 O00255 2/20 0.48
TSHR P16473 1/20 0.47
PARP14 Q460N5 1/20 0.46
PARP10 Q53GL7 1/20 0.46
PARP1 P09874 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13065011 0.93 LMNA (0.55) LMNAKMT2AHPGDALDH1A1CA12
SCHEMBL303740 0.90 LMNA (0.47) LMNAKMT2AHPGDALDH1A1CA12
SCHEMBL3377977 0.89 LMNA (0.52) LMNAKMT2AHPGDALDH1A1PKM
SCHEMBL302061 0.89 LMNA (0.54) LMNAKMT2AHPGDALDH1A1CA12
SCHEMBL3377438 0.85 LMNA (0.54) LMNAKMT2AHPGDALDH1A1PKM
SCHEMBL3377152 0.85 LMNA (0.60) LMNAKMT2AHPGDALDH1A1PKM
SCHEMBL2211106 0.84 LMNA (0.48) LMNAKMT2AHPGDALDH1A1CA12
SCHEMBL3376238 0.84 LMNA (0.50) LMNAKMT2AHPGDALDH1A1PKM
SCHEMBL13065009 0.81 LMNA (0.50) LMNAKMT2AHPGDALDH1A1PKM
SCHEMBL17075498 0.81 LMNA (0.45) LMNAKMT2AHPGDALDH1A1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2342177-B1 NOVEL POTASSIUM CHANNEL BLOCKERS JAPAN TOBACCO INC (JP) 2017-02-15 EP claimed
US-9073834-B2 Potassium channel blockers XENTION LIMITED (GB) 2015-07-07 US claimed
US-20140221337-A1 Potassium Channel Blockers XENTION LIMITED (GB) 2014-08-07 US claimed
JP-2012500836-A 2012-01-12 JP claimed
EP-2342177-A1 NOVEL POTASSIUM CHANNEL BLOCKERS Xention Limited (GB) 2011-07-13 EP claimed
US-20100087428-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US claimed
WO-2010023448-A1 NOVEL POTASSIUM CHANNEL BLOCKERS XENTION LIMITED (GB) 2010-03-04 WO claimed
EP-2342177-B1 NOVEL POTASSIUM CHANNEL BLOCKERS JAPAN TOBACCO INC (JP) 2017-02-15 EP disclosed
US-9447033-B2 Potassium channel blockers JAPAN TOBACCO INC. (JP) 2016-09-20 US disclosed
US-20150259282-A1 Potassium Channel Blockers XENTION LIMITED (GB) 2015-09-17 US disclosed
US-9073834-B2 Potassium channel blockers XENTION LIMITED (GB) 2015-07-07 US disclosed
US-20140221337-A1 Potassium Channel Blockers XENTION LIMITED (GB) 2014-08-07 US disclosed
US-8673901-B2 Potassium channel blockers XENTION LIMITED (GB) 2014-03-18 US disclosed
EP-2342177-A1 NOVEL POTASSIUM CHANNEL BLOCKERS Xention Limited (GB) 2011-07-13 EP disclosed
US-20100087428-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed
WO-2010023448-A1 NOVEL POTASSIUM CHANNEL BLOCKERS XENTION LIMITED (GB) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221337-A1 Potassium Channel Blockers KCNJ2, KCNH2, KCNB1 LMNA 1619/4885KMT2A 386/4885HPGD 3708/4885
US-20100087428-A1 Novel Potassium Channel Blockers HCN4, SCN2B, KCNH2 LMNA 2145/4885KMT2A 1511/4885HPGD 3196/4885
US-20150259282-A1 Potassium Channel Blockers KCNJ2, KCNH2, KCNB1 LMNA 1619/4885KMT2A 386/4885HPGD 3708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.